Cipla launches Q-TIB product globally

30 Nov 2017 Evaluate

Cipla has received an approval for its product Q-TIB from World Health Organisation (WHO). Q-TIB is a novel fixed dose combination in a single tablet. This is the first time that such a combination has been made available in the world. Cipla will market the product globally.

Q-TIB will help prevent tuberculosis infection in people living with HIV. People living with HIV face a challenged immune system and are prone to opportunistic infections, which constitute the major source of premature deaths among them. As per Global TB Report, 2016, by WHO, about one million people died of AIDS-related illness. Most of them succumbed to opportunistic infections, and among them, 400,000 died of tuberculosis.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1405.40 6.60 (0.47%)
25-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1520.55
Dr. Reddys Lab 6217.15
Cipla 1405.40
Zydus Lifesciences 953.50
Lupin 1589.10
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.